Next Article in Journal
High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment
Previous Article in Journal
Assessing Developmental Environmental Risk Factor Exposure in Clinical High Risk for Psychosis Individuals: Preliminary Results Using the Individual and Structural Exposure to Stress in Psychosis-Risk States Scale
Open AccessReview

Identification of Retinal Biomarkers in Alzheimer’s Disease Using Optical Coherence Tomography: Recent Insights, Challenges, and Opportunities

1
Bascom Palmer Eye Institute, Department of Ophthalmology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
2
Poznań City Hospital, 61-285 Poznań, Poland
3
Department of Ophthalmology, University of Warmia and Mazury, 10-082 Olsztyn, Poland
4
Institute for Research in Ophthalmology, Foundation for Ophthalmology Development, 60-554 Poznan, Poland
5
Private Practice, 80-822 Gdańsk, Poland
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2019, 8(7), 996; https://doi.org/10.3390/jcm8070996
Received: 16 June 2019 / Revised: 30 June 2019 / Accepted: 4 July 2019 / Published: 9 July 2019
(This article belongs to the Section Ophthalmology)
This review will highlight recent insights into measuring retinal structure in Alzheimer’s disease (AD). A growing body of evidence indicates that disturbances in retinal blood flow and structure are related to cognitive function, which can severely impair vision. Optical coherence tomography (OCT) is an optical imaging technology that may allow researchers and physicians to gain deeper insights into retinal morphology and clarify the impact of AD on retinal health and function. Direct and noninvasive measurement of retinal morphology using OCT has provided useful diagnostic and therapeutic indications in several central nervous system (CNS) diseases, including AD, multiple sclerosis, and Parkinson disease. Despite several limitations, morphology assessment in the retinal layers is a significant advancement in the understanding of ocular diseases. Nevertheless, additional studies are required to validate the use of OCT in AD and its complications in the eye. View Full-Text
Keywords: Alzheimer’s disease; central nervous system diseases; ganglion cell layer; optical coherence tomography; retinal nerve fiber layer Alzheimer’s disease; central nervous system diseases; ganglion cell layer; optical coherence tomography; retinal nerve fiber layer
Show Figures

Figure 1

MDPI and ACS Style

Cabrera DeBuc, D.; Gaca-Wysocka, M.; Grzybowski, A.; Kanclerz, P. Identification of Retinal Biomarkers in Alzheimer’s Disease Using Optical Coherence Tomography: Recent Insights, Challenges, and Opportunities. J. Clin. Med. 2019, 8, 996.

AMA Style

Cabrera DeBuc D, Gaca-Wysocka M, Grzybowski A, Kanclerz P. Identification of Retinal Biomarkers in Alzheimer’s Disease Using Optical Coherence Tomography: Recent Insights, Challenges, and Opportunities. Journal of Clinical Medicine. 2019; 8(7):996.

Chicago/Turabian Style

Cabrera DeBuc, Delia; Gaca-Wysocka, Magdalena; Grzybowski, Andrzej; Kanclerz, Piotr. 2019. "Identification of Retinal Biomarkers in Alzheimer’s Disease Using Optical Coherence Tomography: Recent Insights, Challenges, and Opportunities" J. Clin. Med. 8, no. 7: 996.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop